Evaluation of the Diagnostic Accuracy of Superparamagnetic Iron Oxide Nanoparticles on Breast Cancer: A Systematic Review and Meta-analysis

Document Type : Review Article


1 Department of Oncology, School of Medicine, The Affiliated Zhongda Hospital of Southeast University, Nanjing, China

2 Department of Obstetrics and Gynecology, The second Affiliated Hospital of Soochow University, Suzhou, China

3 Medical Center of Digestive Disease, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China


Background and aim: The present study was conducted to evaluate the diagnostic accuracy of Superparamagnetic iron oxide nanoparticles in breast cancer.
Material and methods: We examined all international databases, including PubMed, Scopus, Science Direct, ISI, Web of Knowledge, and Embase, searching until January 2023 based on keywords related to the objectives of the study. Based on the PRISMA 2020 checklist, the current study was conducted, and the Google Scholar search engine was also used to find related articles. A fixed-effect model and inverse-variance method were used to calculate the 95% confidence interval risk ratio. The meta-analysis was conducted using Stata/MP v. 17 software.
Results: The abstracts of 477 articles were reviewed, and 51 articles were selected for full-text review, of which 15 articles were included in the meta-analysis. The risk ratio of patient detection rate between superparamagnetic iron oxide nanoparticles and the standard method was 1.02 (RR, 1.02 95% CI 0.52, 1.53; p>0.05). Compared to the control group, the superparamagnetic iron oxide nanoparticles group showed a higher superiority in extracting more SLN (RR, 1.07 95% CI 0.52, 1.61; p<0.05).
Conclusions: Based on the findings of the present meta-analysis, superparamagnetic iron oxide nanoparticles can be a suitable alternative to standard methods in sentinel lymph node detection in breast cancer patients. It is suggested to study larger populations to confirm the present evidence.


Main Subjects

[1]  Arisio R, Borella F, Porpiglia M, Durando A, Bellino R, Bau MG, et al. Axillary dissection vs. no axillary dissection in breast cancer patients with positive sentinel lymph node: a single institution experience. in vivo. 2019;33(6):1941-7. https://doi.org/10.21873/invivo.11689.
[2]  Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection. Journal of surgical oncology. 2010;102(2):111-8. https://doi.org/10.1002/jso.21535.
[3]  Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. Journal of the National Cancer Institute. 2006;98(9):599-609. https://doi.org/10.1093/jnci/djj158.
[4]  Aldenhoven L, Frotscher C, Körver-Steeman R, Martens MH, Kuburic D, Janssen A, et al. Sentinel lymph node mapping with superparamagnetic iron oxide for melanoma: a pilot study in healthy participants to establish an optimal MRI workflow protocol. BMC cancer. 2022;22(1):1-7. https://doi.org/10.1186/s12885-022-10146-w.
[5]  Alipour S, Omranipour R, editors. Diseases of the Breast during Pregnancy and Lactation. Springer; 2020.
[6]  Johnson L, Pinder SE, Douek M. Deposition of superparamagnetic iron‐oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection. Histopathology. 2013;62(3):481-6. https://doi.org/10.1111/his.12019.
[7]  Rezai M, Kocdor MA, Canturk NZ, editors. Breast Cancer Essentials: Perspectives for Surgeons. Springer International Publishing; 2021.
[8]  Teshome M, Wei C, Hunt KK, Thompson A, Rodriguez K, Mittendorf EA. Use of a magnetic tracer for sentinel lymph node detection in early-stage breast cancer patients: a meta-analysis. Annals of surgical oncology. 2016;23:1508-14. https://doi.org/10.1245/s10434-016-5135-1.
[9]  Tugwell P, Tovey D. PRISMA 2020. Journal of Clinical Epidemiology. 2021;134:A5-6. https://doi.org/10.1016/j.jclinepi.2021.04.008.
[10] Spiekerman van Weezelenburg MA, van Haaren ER, Aldenhoven L, Frotscher CN, Körver-Steeman R, van Bastelaar J, et al. An adapted protocol for magnetic localisation of nonpalpable breast cancer lesions and sentinel lymph nodes using a magnetic seed and superparamagnetic iron oxide tracer. Journal of Surgical Oncology. 2023;127(5):776-81. https://doi.org/10.1002/jso.27197.
[11] CENGİZ MB. Neoadjuvan tedavi almış meme kanseri hastalarında aksiller lenf nodu örneklemesinde süperparamanyetik demir oksit iyonlarının (SPIO) yeri/Superparamagnetic iron oxide (SPIO) in axillary lymph node mapping after neoadjuvant chemotheraphy. 2023.
[12] Vidya R, Khosla M, Laws S, Harvey J, Kaushik M, Mullapudi NA, et al. Axillary sentinel lymph node identification using superparamagnetic iron oxide versus radioisotope in early stage breast cancer: The UK SentiMag trial (SMART study). The Surgeon. 2022;21(2):128-34. https://doi.org/10.1016/j.surge.2022.04.006.
[13] Giménez-Climent J, Marín-Hernández C, Fuster-Diana CA, Torró-Richart JA, Navarro-Cecilia J. Sentinel lymph node biopsy in breast cancer after neoadjuvant therapy using a magnetic tracer versus standard technique: A multicentre comparative non-inferiority study (IMAGINE-II). International Journal of Surgery Open. 2021;35:100404. https://doi.org/10.1016/j.ijso.2021.100404.
[14] Hersi AF, Pistiolis L, Dussan Luberth C, Vikhe-Patil E, Nilsson F, Mohammed I, et al. Optimizing dose and timing in magnetic tracer techniques for sentinel lymph node detection in early breast cancers: the prospective multicenter SentiDose trial. Cancers. 2021;13(4):693. https://doi.org/10.3390/cancers13040693.
[15] Hamzah JL, Tan BK, Tan V, Madhukumar P, Lim SZ, Sim YR, et al. A pilot study comparing Sentimag/Sienna versus standard modality for sentinel lymph node identification in patients with breast cancer. The breast journal. 2020;26(5):1074-7. https://doi.org/10.1111/tbj.13660.
[16] Rubio IT, Rodriguez-Revuelto R, Espinosa-Bravo M, Siso C, Rivero J, Esgueva A. A randomized study comparing different doses of superparamagnetic iron oxide tracer for sentinel lymph node biopsy in breast cancer: The SUNRISE study. European Journal of Surgical Oncology. 2020;46(12):2195-201. https://doi.org/10.1016/j.ejso.2020.06.018.
 [17] Makita M, Manabe E, Kurita T, Takei H, Nakamura S, Kuwahata A, et al. Moving a neodymium magnet promotes the migration of a magnetic tracer and increases the monitoring counts on the skin surface of sentinel lymph nodes in breast cancer. BMC Medical Imaging. 2020;20:1-11. https://doi.org/10.1186/s12880-020-00459-2.
[18] Taruno K, Kurita T, Kuwahata A, Yanagihara K, Enokido K, Katayose Y, et al. Multicenter clinical trial on sentinel lymph node biopsy using superparamagnetic iron oxide nanoparticles and a novel handheld magnetic probe. Journal of Surgical Oncology. 2019;120(8):1391-6. https://doi.org/10.1002/jso.25747.
[19] Alvarado MD, Mittendorf EA, Teshome M, Thompson AM, Bold RJ, Gittleman MA, et al. SentimagIC: a non-inferiority trial comparing superparamagnetic iron oxide versus technetium-99m and blue dye in the detection of axillary sentinel nodes in patients with early-stage breast cancer. Annals of surgical oncology. 2019;26:3510-6. https://doi.org/10.1245/s10434-019-07577-4.
[20] Karakatsanis A, Hersi AF, Pistiolis L, Olofsson Bagge R, Lykoudis PM, Eriksson S, et al. Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). Journal of British Surgery. 2019;106(6):720-8. https://doi.org/10.1002/bjs.11110.
 [21] Karakatsanis A, Olofsson H, Stålberg P, Bergkvist L, Abdsaleh S, Wärnberg F. Simplifying logistics and avoiding the unnecessary in patients with breast cancer undergoing sentinel node biopsy. A prospective feasibility trial of the preoperative injection of super paramagnetic iron oxide nanoparticles. Scandinavian Journal of Surgery. 2018;107(2):130-7. https://doi.org/10.1177/1457496917738867.
 [22] Ghilli M, Carretta E, Di Filippo F, Battaglia C, Fustaino L, Galanou I, et al. The superparamagnetic iron oxide tracer: a valid alternative in sentinel node biopsy for breast cancer treatment. European journal of cancer care. 2017;26(4):e12385. https://doi.org/10.1111/ecc.12385.
[23] Houpeau JL, Chauvet MP, Guillemin F, Bendavid-Athias C, Charitansky H, Kramar A, et al. Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: the French Sentimag feasibility trial. Journal of surgical oncology. 2016;113(5):501-7. https://doi.org/10.1002/jso.24164.
[24] Ahmed M, Anninga B, Goyal S, Young P, Pankhurst QA, Douek M, et al. Magnetic sentinel node and occult lesion localization in breast cancer (MagSNOLL Trial). Journal of British Surgery. 2015;102(6):646-52. https://doi.org/10.1002/bjs.9800.
[25] Taruno K, Kuwahata A, Sekino M, Nakagawa T, Kurita T, Enokido K, et al. Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation. Cancers. 2022;14(6):1409. https://doi.org/10.3390/cancers14061409.
[26] Karakatsanis A, Daskalakis K, Stålberg P, Olofsson H, Andersson Y, Eriksson S, et al. Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. Journal of British Surgery. 2017;104(12):1675-85. https://doi.org/10.1002/bjs.10606.
[27] Bazire L, Alran S, El Bamrani S, Gaujal L, Vincent-Salomon A, Tardivon A, et al. Radiation therapy after sentinel lymph node biopsy for early stage breast cancer using a magnetic tracer: results of a single institutional prospective study of tolerance. Cancer/Radiothérapie. 2019;23(1):23-7. https://doi.org/10.1016/j.canrad.2018.03.008.
Volume 5, Issue 1
March 2023
Pages 27-34
  • Receive Date: 05 January 2023
  • Revise Date: 12 February 2023
  • Accept Date: 25 February 2023
  • First Publish Date: 01 March 2023